Concord Wealth Partners Vaxart, Inc. Transaction History
Concord Wealth Partners
- $710 Million
- Q3 2025
A detailed history of Concord Wealth Partners transactions in Vaxart, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 75 shares of VXRT stock, worth $27. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 75
-0.0%
Holding current value
$27
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VXRT
# of Institutions
55Shares Held
8.08MCall Options Held
66.1KPut Options Held
0-
Marshall Wace, LLP London, X01.95MShares$722,6230.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$656,5080.0% of portfolio
-
State Street Corp Boston, MA851KShares$314,9140.0% of portfolio
-
Squarepoint Ops LLC New York, NY447KShares$165,3350.0% of portfolio
-
Northern Trust Corp Chicago, IL409KShares$151,3960.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $46.8M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...